Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group
- PMID: 1510385
- DOI: 10.1002/ana.410320714
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group
Abstract
We examine the evidence for free radical involvement and oxidative stress in the pathological process underlying Parkinson's disease, from postmortem brain tissue. The concept of free radical involvement is supported by enhanced basal lipid peroxidation in substantia nigra in patients with Parkinson's disease, demonstrated by increased levels of malondialdehyde and lipid hydroperoxides. The activity of many of the protective mechanisms against oxidative stress does not seem to be significantly altered in the nigra in Parkinson's disease. Thus, activities of catalase and glutathione peroxidase are more or less unchanged, as are concentrations of vitamin C and vitamin E. The activity of mitochondrial superoxide dismutase and the levels of the antioxidant ion zinc are, however, increased, which may reflect oxidative stress in substantia nigra. Levels of reduced glutathione are decreased in nigra in Parkinson's disease; this decrease does not occur in other brain areas or in other neurodegenerative illnesses affecting this brain region (i.e., multiple system atrophy, progressive supranuclear palsy). Altered glutathione metabolism may prevent inactivation of hydrogen peroxide and enhance formation of toxic hydroxyl radicals. In brain material from patients with incidental Lewy body disease (presymptomatic Parkinson's disease), there is no evidence for alterations in iron metabolism and no significant change in mitochondrial complex I function. The levels of reduced glutathione in substantia nigra, however, are reduced to the same extent as in advanced Parkinson's disease. These data suggest that changes in glutathione function are an early component of the pathological process of Parkinson's disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.Acta Neurol Scand Suppl. 1993;146:6-13. Acta Neurol Scand Suppl. 1993. PMID: 8333254 Review.
-
Oxidative mechanisms in nigral cell death in Parkinson's disease.Mov Disord. 1998;13 Suppl 1:24-34. Mov Disord. 1998. PMID: 9613715 Review.
-
What process causes nigral cell death in Parkinson's disease?Neurol Clin. 1992 May;10(2):387-403. Neurol Clin. 1992. PMID: 1584181 Review.
-
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.Ann Neurol. 1994 Sep;36(3):348-55. doi: 10.1002/ana.410360305. Ann Neurol. 1994. PMID: 8080242
-
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.Ann Neurol. 1994 Jan;35(1):38-44. doi: 10.1002/ana.410350107. Ann Neurol. 1994. PMID: 8285590
Cited by
-
Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson's disease brains.Neurochem Res. 2013 Jan;38(1):186-200. doi: 10.1007/s11064-012-0907-x. Epub 2012 Oct 16. Neurochem Res. 2013. PMID: 23070472
-
CuII (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease.Br J Pharmacol. 2020 Feb;177(3):656-667. doi: 10.1111/bph.14881. Epub 2020 Jan 14. Br J Pharmacol. 2020. PMID: 31655003 Free PMC article.
-
Oxidative imbalance in Alzheimer's disease.Mol Neurobiol. 2005;31(1-3):205-17. doi: 10.1385/MN:31:1-3:205. Mol Neurobiol. 2005. PMID: 15953822 Review.
-
Vesicular monoamine transporter 2: role as a novel target for drug development.AAPS J. 2006 Nov 10;8(4):E682-92. doi: 10.1208/aapsj080478. AAPS J. 2006. PMID: 17233532 Free PMC article. Review.
-
Disubstituted Dithiolethione ACDT Exerts Neuroprotective Effects Against 6-Hydroxydopamine-Induced Oxidative Stress in SH-SY5Y Cells.Neurochem Res. 2019 Aug;44(8):1878-1892. doi: 10.1007/s11064-019-02823-3. Epub 2019 Jun 4. Neurochem Res. 2019. PMID: 31190314
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical